ReviewTherapeutic advances in urology
Current standard of care in treatment of bladder pain syndrome/interstitial cystitis.
Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sacral Neuromodulation Test-Phase Success in Bladder Pain Syndrome: Systematic Review and Meta-Analysis.International urogynecology journal · 2026Review
- Physiotherapeutic Management of Painful Bladder Syndrome/Interstitial Cystitis: A Systematic Review of the Literature.International urogynecology journal · 2026Review
- The value of a non-invasive bladder sensitivity paradigm in chronic pelvic pain.Reproduction & fertility · 2026Article
- TP63 regulates pyroptosis via NF-κB/NLRP3/caspase-1 signaling in interstitial cystitis: insights from single-cell sequencing.Open medicine (Warsaw, Poland) · 2026Article
- The role of netrin-1 in the diagnosis and prognosis of bladder pain syndrome /interstitial cystitis: a comparative study.World journal of urology · 2025Article
- Antioxidant, anti-inflammatory and Uroprotective effects of LAMOTRIGINE Cinnamaldehyde silver complex in cyclophosphamide-induced cystitis.Toxicology research · 2025Article
- Hispidulin targets PTGS2 to improve cyclophosphamide-induced cystitis by suppressing NLRP3 inflammasome.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Divergent histopathological and molecular patterns in chemically induced interstitial cystitis/bladder pain syndrome rat models.Scientific reports · 2024Article
- This pain drives me crazy: Psychiatric symptoms in women with interstitial cystitis/bladder pain syndrome.World journal of psychiatry · 2024Article
- Cannabidiol as a Promising Therapeutic Option in IC/BPS: In Vitro Evaluation of Its Protective Effects against Inflammation and Oxidative Stress.International journal of molecular sciences · 2023Article
- Uroprotective and pain-relieving effect of dietary supplementation with micronized palmitoyl-glucosamine and hesperidin in a chronic model of cyclophosphamide-induced cystitis.Frontiers in veterinary science · 2023Article
- New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome.BMB reports · 2022Review
- Identification of Immune-Related Genes and Small-Molecule Drugs in Interstitial Cystitis/Bladder Pain Syndrome Based on the Integrative Machine Learning Algorithms and Molecular Docking.Journal of immunology research · 2022Article
- The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis.Frontiers in immunology · 2022Article
- Endoscopic injection of botulinum toxin to prevent pouch contractions in a patient with Indiana pouch diversion.Therapeutic advances in urologyArticle
- Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner's lesions or glomerulations: systematic review and meta-analysis.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a debilitating, systemic pain syndrome with a cardinal symptom of bladder related pain with associated systemic symptoms. It is characterized by an inflammation that partially or completely destroys the mucus membrane and can extend into the muscle layer; however, the etiology and pathogenesis is still enigmatic. It has been suggested that mast cell activation, defects in the glycosaminoglycan layer, non-functional proliferation of bladder epithelial cells, neurogenic inflammation, microvascular abnormalities in the submucosal layer, autoimmunity and infectious causes may cause BPS/IC. Available treatment options include general relaxation techniques, patient education, behavioral treatments, physical therapy, multimodal pain therapy, oral (amitriptyline, cimetidine, hydroxyzine) and intravesical treatments (heparin, lidocaine, hyaluronic acid and chondroitin sulfate), hydrodistension and other more invasive treatments. Available treatments are mostly not based on a high level of evidence. Lack of understanding of disease mechanisms has resulted in lack of targeted therapies on this area and a wealth of empirical approaches with usually inadequate efficacy. The aim of this article is to review the available evidence on the pathophysiological mechanisms of BPS/IC as they relate to available treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.